Moderna, AstraZeneca announce positive AZD8601 data from Phase 2 study in heart failure

Moderna (MRNA -0.1%) announces positive data from the the Phase 2 EPICCURE study evaluating the use of an mRNA therapeutic that encodes for vascular endothelial growth factor-A (AZD8601) in patients undergoing coronary artery bypass grafting (CABG).